FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      
           
This page is updated frequently with new Platelet-related patent applications. Subscribe to the Platelet RSS feed to automatically get the update: related Platelet RSS feeds. RSS updates for this page: Platelet RSS RSS


Blood separating vessel for extracting autologous platelets, and apparatus for extracting autologous platelets

Date/App# patent app List of recent Platelet-related patents
07/24/14
20140206716
 Methods and compositions for the assessment of drug response patent thumbnailnew patent Methods and compositions for the assessment of drug response
The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent.
07/24/14
20140206644
 Methods and compositions for inhibiting cellular proliferation and surgical adhesion patent thumbnailnew patent Methods and compositions for inhibiting cellular proliferation and surgical adhesion
The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery.
07/24/14
20140205582
 Megakaryocyte progenitor cells for production of platelets patent thumbnailnew patent Megakaryocyte progenitor cells for production of platelets
Provided herein are methods of generating megakaryocyte lineage cells from hematopoietic stem cells in the absence of feeder cells and serum. The megakaryocyte progenitor cells (mkps) generated as described result in rapid production of significant numbers of platelets when administered in vivo..
07/24/14
20140205514
 Blood separating vessel for extracting autologous platelets, and apparatus for extracting autologous platelets patent thumbnailnew patent Blood separating vessel for extracting autologous platelets, and apparatus for extracting autologous platelets
Provided is a blood separating vessel for extracting autologous platelets, and an apparatus for extracting autologous platelets. The blood separating vessel for extracting autologous platelets comprises: a main body defining an internal space divided into an upper fluid chamber and a lower fluid chamber; an upper cover disposed to seal an upper portion of the upper fluid chamber; a lower cover disposed to seal a lower portion of the lower fluid chamber, the lower cover being coupled such that an outer peripheral surface of the lower cover is elevatable in a state of being in close contact along an inner peripheral surface of the lower fluid chamber by an external force applied upward; and a fluid collection part dividing the internal space into the upper fluid chamber and the lower fluid chamber and including a fluid passage protruding upward to communicate the upper fluid chamber with the lower fluid chamber..
07/24/14
20140205176
 Optical platelet counter method patent thumbnailnew patent Optical platelet counter method
Platelets or blood cells are detected in a fluid sample by adjusting a focal depth of a microscope through a range of values, the microscope having a mounted sample and an objective lens adapted with one or both of (a) a spherical aberration correction unmatched to a utilized cover plate for the sample, or (2) a numerical aperture unmatched to a utilized illumination source for the sample. Images are recorded at different specific focal depths and in multiple z planes of a fluid bearing the platelets, where the position of platelets may overlap on different of the multiple z planes that are recorded, the images recorded through the cover plate, thus causing the generation of a specific light-dark pattern indicative of platelets at particular positions and at multiple depths in the fluid media.
07/17/14
20140200256
 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements patent thumbnailAcetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements..
07/17/14
20140200240
 Methods for determining patient response to anti-platelet aggregation therapy patent thumbnailMethods for determining patient response to anti-platelet aggregation therapy
Diagnostic methods for determining whether an individual will benefit from a particular anti-thrombotic therapeutic agent are disclosed. The methods involve obtaining a biological sample that comprises platelets, from a patient who has been pre-administered a particular therapeutic agent, which is an antagonist of a receptor associated with the biochemical pathways involved in platelet aggregation, and exposing the platelets to an agonist of the receptor.
07/17/14
20140196684
 Spark plug for an internal combustion engine patent thumbnailSpark plug for an internal combustion engine
The invention relates to a spark plug for an internal combustion engine, in particular a gas engine. The spark plug includes a middle electrode and at least one earth electrode group, each comprising one or more earth electrode platelets.
07/10/14
20140194407
 Novel antiplatelet agent patent thumbnailNovel antiplatelet agent
R3 is an optionally substituted aryl or an optionally substituted heteroaryl, or pharmaceutically acceptable salt thereof as an active ingredient.. .
07/10/14
20140193590
 Surface-modified, exfoliated nanoplatelets as mesomorphic structures in solutions and polymeric matrices patent thumbnailSurface-modified, exfoliated nanoplatelets as mesomorphic structures in solutions and polymeric matrices
A method of manufacturing a nanocomposite having a continuous organic phase and oligomer-modified nanoplatelet mesomorphic structures, wherein the oligomer has a molecular weight of at least 100 g/mol.. .
07/10/14
20140193485
Orally administrable liposomally encapsulated reduced glutathione, with ace inhibitors for reversal and prevention of oxidation of cholesterol and of low density lipoprotein
The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized hdl and oxidized ldl. The invention also proposes combining liposomal encapsulated glutathione with ace inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized hdl and oxidized ldl.
07/10/14
20140193402
Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
07/03/14
20140187643
Method of treatment with anti-inflammatory and analgesic compounds which are gi-, renal-, and platelet-sparing
Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having gi-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.. .
07/03/14
20140186874
Immature platelet enumeration systems and methods
Embodiments of the present invention encompass automated systems and methods for analyzing immature platelet parameters in an individual based on a biological sample obtained from blood of the individual. Exemplary techniques involve correlating aspects of direct current (dc) impedance, radiofrequency (rf) conductivity, and/or light measurement data obtained from the biological sample with an evaluation of immature platelet conditions in the individual..
07/03/14
20140186455
Tissue repair system
An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid.
07/03/14
20140186349
Human cdr-grafted antibody and antibody fragment thereof
A human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human cc chemokine receptor 4 (ccr4) but does not react with a human blood platelet; a human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of ccr4 and has a cytotoxic activity against a ccr4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.. .
07/03/14
20140186320
Methods and compositions for the treatment, prevention, and alleviation of bone and cartilage diseases or injuries and hair loss
The present invention provides pharmaceutical compositions, and methods of preparation and use for the treatment, prevention or alleviation of bone and cartilage diseases or injuries and hair loss. The present invention discloses a method and a pharmaceutical composition comprising mesenchymal stem cells, platelets, activating factors and scaffolding materials for the treatment, prevention, or alleviation of bone diseases, bone injuries or hair loss, and a method and a pharmaceutical composition further comprising dexamethasone for the treatment, prevention, or alleviation of cartilage diseases or injuries..
07/03/14
20140186217
Blood coagulation system analyzing method and blood coagulation system analyzing device
A blood coagulation analysis device and method in which information relating to the coagulability of blood is evaluated based on a change generated in a permittivity measured in a coagulation process of the blood due to addition of a substance that activates or inactivates platelets to the blood.. .
07/03/14
20140185031
Systems and methods for platelet count with clump adjustment
Embodiments of the present invention encompass automated systems and methods for analyzing platelet parameters in an individual based on a biological sample obtained from blood of the individual. Exemplary techniques involve correlating aspects of direct current (dc) impedance and/or light measurement data obtained from the biological sample with an evaluation of platelet conditions in the individual..
06/26/14
20140179766
Identification of thrombosis or bleeding risk in an individual with and without anti-platelet therapy
The invention relates to a method for identification of an individual at increased risk of thrombosis or an atherothrombotic event, or a major bleeding event, comprising a step of assaying a biological sample from the individual for the presence of a snp in the ppargc1β, cntn4, lzts1 and kcne4 genes, wherein the presence of a snp in the ppargc1β, cntn4, lzts1 and kcne4 genes correlates with the individual being at increased risk of thrombosis or an atherothrombotic event, or a major bleeding event. Typically, the snp is selected from the snps provided in tables 1 and 2.
06/26/14
20140179602
Viral inactivated biological mixture
The invention relates to a viral inactivated biological liquid or dry mixture and to its preparation. Principally, the invention relates, but is not limited, to a mixture derived from a platelet source..
06/19/14
20140171469
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
Pyrazole derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
06/19/14
20140170741
Hepatic fibrosis detection apparatus and system
A hepatic fibrosis detection apparatus and system include an input device, for receiving age and serum biochemical variables, the serum biochemical variables at least including blood platelet, hyaluronic acid, serum direct bilirubin, pro-thrombin time, serum glutamic pyruvic transaminase and serum glutamic oxaloacetic transaminase; a classifier, for performing hepatic fibrosis staging according to the age and serum biochemical variables received by the input device and transient elastography imaging data; and an output device, for outputting a result of the hepatic fibrosis staging of the classifier. The system provides various benefits such as non-invasiveness, high practicability, simple method, low cost and high safety..
06/19/14
20140170410
Method for applying a coating to a substrate, coating, and use of particles
The present invention relates to a method for applying a coating to a substrate using cold plasma, wherein particles provided with a polymer coating are fed into a cold plasma at less than 3,000 k and the particles activated by this are deposited on a substrate. The present invention furthermore relates to a substrate coating which can be obtained by the methods according to the invention.
06/19/14
20140166500
Method for producing thin graphene nanoplatelets and precusor thereof
Disclosed is a method of producing thin graphene nanoplatelets, and the method includes the steps of providing a carbon precursor and a filling material, using the carbon precursor as a binding agent to mix with the filling material thoroughly, producing a composite material through a forming process, performing a heat treatment of the composite material under an atmosphere and at different temperatures to improve the electrical conductivity and adjust to an appropriate binding strength, perform a carbon conversion of the composite material with a good graphite cyrstallinity to produce a layered graphite structure of a thin graphene nanoplatelet precursor, while obtaining high quality graphene by performing an electrochemical process of the thin graphene nanoplatelet precursor, so as to achieve the mass production of the high quality thin graphene nanoplateletes with a low cost.. .
06/19/14
20140165878
Interference pigment with high color intensity and method of manufacturing the same
The interference pigment with high color intensity includes: a platelet-shaped substrate including at least one of natural mica, synthetic mica, alumina flakes, glass flakes, and iron oxide flakes; a lower first metal oxide layer formed of fe2o3 on the platelet-shaped substrate; a second metal oxide layer formed of mgo.sio2 on the lower first metal oxide layer; and an upper first metal oxide layer formed of fe2o3 on the second metal oxide layer.. .
06/12/14
20140163090
Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have essential thrombocythemia (et). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having et..
06/12/14
20140162364
Method for producing a porous calcium polyphosphate structure
A method for producing a porous calcium polyphosphate structure, which comprises the steps of mixing monocalcium phosphate (mcp) with silicic acid, and sintering the mixture at a predefined temperature or temperatures for a predefined time, after which the porous calcium polyphosphate is obtained. The method allows a porous biomaterial with a controllable porosity to be obtained, and which also has the ability to activate the platelets in a plasma rich in platelets and cause the release of growth factors from the platelets..
06/12/14
20140161811
Platelet derived growth factor receptor supports cytomegalovirus infectivity
The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the herpesviridae family, and more particularly to cytomegalovirus (cmv).. .
06/12/14
20140158604
Platelet storage container
Compositions, methods, devices and media are provided for platelet storage container that prevents bacterial growth in the stored platelets. The invention relates to blood bank needs in safely storing platelets collected from donors for more than 5 days at room temperature.
06/12/14
20140158556
Platelets storage container
A storage container for pathogen reduction and maintaining ph levels for preserved platelets concentrates and other blood products.. .
06/05/14
20140155680
Angiogenesis initiation and growth
Methods for promoting angiogenesis comprising administering platelet-rich plasma to a site and stimulating the site with an electromagnetic field. Platelets include platelet-rich plasma and compositions can further include stem cells such as adipose stromal cells and cells derived from bone marrow aspirate.
06/05/14
20140155544
Tire with component comprised of rubber composition containing silica and graphene platelet reinforcement
This invention relates to a rubber composition comprised of diene-based elastomer, precipitated silica and nano-scale exfoliated graphene platelets. A tire is provided having a component comprised of such rubber composition..
06/05/14
20140155351
Process for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride
Disclosed herein are a process or method for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride. The process comprises preparation of prasugrel by acetylation in solvents which have low boiling point and/or low toxicity, and the process not only avoids using solvents which have high boiling point and/or high toxicity such as toluene, acetonitrile and so on, but also resolves the problem about thermal instability of prasugrel, and the loss of prasugrel is reduced, as well as the yield is raised.
06/05/14
20140154941
Unitary graphene matrix composites containing carbon or graphite fillers
A unitary graphene matrix composite comprising: (a) a unitary graphene matrix containing an oxygen content of 0.001% to 10% by weight, obtained from heat-treating a graphene oxide gel at a temperature higher than 100° c. And contains no discrete graphene platelets derived from the graphene oxide gel; (b) a carbon or graphite filler phase selected from carbon or graphite fiber, carbon or graphite nano-fiber, carbon nano-tube, carbon nano-rod, meso-phase carbon particle, meso-carbon micro-bead, exfoliated graphite flake with a thickness greater than 100 nm, exfoliated graphite or graphite worm, coke particle, needle coke, carbon black or acetylene black particle, activated carbon particle, or a combination thereof.
06/05/14
20140154810
Method for conducting platelet aggregation analysis
A cartridge device having a receiving portion for receiving a blood sample and a jack portion for receiving a plug; a stirring device for circulating the blood sample within the receiving portion; and an electrode holder having at least one incorporated electrode wire pair; wherein the electrode holder is attachable to the cell such that one end of the at least one electrode wire pair forms a sensor unit for measuring the electrical impedance between the two electrode wires of the at least one electrode wire pair within the blood sample and that the opposite end of the at least one electrode wire pair forms a plug portion being connectable directly to the plug for an electrical connection of the sensor unit to an analyser.. .
06/05/14
20140154665
Apparatuses, compositions, and methods for prolonging survival of platelets
The present invention provides modified platelets having a reduced platelet clearance and methods for reducing platelet clearance. Also provided are compositions for the preservation of platelets.
06/05/14
20140154234
Method for generating thrombin
Methods of generating thrombin and methods of applying a clotting tissue sealant to a site on a subject are provided. A blood component comprising platelets can be obtained from the subject.
05/29/14
20140147648
Unitary graphene layer or graphene single crystal
A unitary graphene layer or graphene single crystal containing closely packed and chemically bonded parallel graphene planes having an inter-graphene plane spacing of 0.335 to 0.40 nm and an oxygen content of 0.01% to 10% by weight, which unitary graphene layer or graphene single crystal is obtained from heat-treating a graphene oxide gel at a temperature higher than 100° c., wherein the average mis-orientation angle between two graphene planes is less than 10 degrees, more typically less than 5 degrees. The molecules in the graphene oxide gel, upon drying and heat-treating, are chemically interconnected and integrated into a unitary graphene entity containing no discrete graphite flake or graphene platelet.
05/29/14
20140147537
Fruit extracts
Provided are methods of making an extract of fruit of the solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract. The methods involve preparing a start mix of homogenised fruit; separating a water soluble fraction from fruit solids; filtration of the water soluble fraction; and concentration of active agents in the filtration permeate.
05/22/14
20140142613
Instrument for capturing free thrombi
An instrument captures free thrombi by inhibiting blood coagulation reaction at the stage of primary hemostasis, in which platelets are involved, and at the stage of coagulation thrombus formation, in which blood coagulation factors are involved, thereby securely capturing free thrombi and extending the available time of the instrument.. .
05/22/14
20140142321
Benzimidazole derivatives as pi3 kinase inhibitors
This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ oh kinase family (hereinafter pi3 kinases), suitably, pi3kα, pi3kδ, pi3kβ, and/or pi3kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries.
05/22/14
20140141071
Orally administrable liposomally encapsulated reduced glutathione, with n-o enhancing compounds for reversal and prevention of oxidation of cholesterol and of low density lipoprotein
The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized hdl and oxidized ldl. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized hdl and oxidized ldl.
05/22/14
20140141047
Selection of platelet rich plasma components via mineral binding
Mineral coated devices and methods for delivering an autologous biological molecule using the mineral coated devices are disclosed. The mineral coated devices allow for the isolation and delivery of a biological molecule obtained from the same subject to avoid the safety concerns of current biological therapies obtained by recombinant methods and purification from animal sources.
05/22/14
20140140989
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
This invention relates generally to monoclonal antibodies that recognize cd47, more specifically to cd47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, amenia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.. .
05/15/14
20140134724
Culture medium for human mesenchymal stem cells
A culture medium for human mesenchymal stem cells (hmsc) includes a mesenchymal stem cell basal medium; human leucocyte/platelet coat lysate; insulin; sodium selenite; ethanolamine; and basic fibroblast growth factor. This culture medium is effective for growing hmsc lines, including those which do not grow in culture medium normally used for this type of cell..
05/15/14
20140134355
Treated graphene nanoplatelets for inflatable structure barrier layers
An air-impermeable fabric is disclosed. The air-impermeable fabric has a fabric substrate, which may also be referred to as a base fabric.
05/15/14
20140134354
Barrier layer for inflatable structures
An air-impermeable fabric is disclosed. The air-impermeable fabric has a fabric substrate, which may also be referred to as a base fabric.
05/15/14
20140134211
Formulations and methods for recovery from dental surgery
Methods and formulations for the improvement of recovery following bone-impacting injury or surgery. The formulations disclosed herein preferably include a blood component with a pharmaceutical agent.
05/15/14
20140134176
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to pdgf-b. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same.
05/15/14
20140134051
Automated platelet function analyzer and its analytical methods
An automated platelet function analyzer includes a sampling vessel, a preparation vessel, an analysis vessel, a sampling needle, a blood sample syringe, a platelet agonist syringe, an analysis solution syringe and a blood mixing device. A method for platelet analysis is also disclosed..
05/08/14
20140128587
Nucleic acid modulators of glycoprotein vi
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein gpvi to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore gpvi function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation.
05/08/14
20140128454
Nucleic acid modulators of glycoprotein vi
The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein gpvi to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore gpvi function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation.
05/08/14
20140127815
Method for producing polyploidized megakaryocyte and platelets
An object of the present invention is to provide a method of promoting polyploidization of megakaryocytes and thereby producing highly polyploidized megakaryocytes, a method of efficiently producing platelets from polyploidized megakaryocytes, and the like. The present invention provides a method of producing polyploidized megakaryocytes comprising a step of forcing expression of an apoptosis suppressor gene in megakaryocytes before polyploidization and culturing the resulting cells..
05/08/14
20140127314
Compositions, uses, and preparation of platelet lysates
In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component.


Popular terms: [SEARCH]

Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2605

3315

2 - 1 - 71